- Conditions
- Heart Failure
- Interventions
- Implantation of a QuickFlex® μ Model 1258T LV Lead
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,930 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 67 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 5,306
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Squamous Cell Carcinoma, Non-Small-Cell Lung
- Interventions
- Abraxane (Induction), Carboplatin (Induction), Abraxane (Maintenance), Best Supportive Care (Maintenance)
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 427 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 91
- States / cities
- Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 73 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Iodofiltic acid I 123
- Drug
- Lead sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 33 more
- Conditions
- Leukemia
- Interventions
- clofarabine, cytarabine, methotrexate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Downey, California • Long Beach, California + 65 more
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Carboplatin, Cisplatin, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Proton Beam Radiation Therapy
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 178
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 128 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Tesaglitazar, Pioglitazone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 107 more
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Echocardiography Test, Electrocardiography, Lumbar Puncture, Mesna, Methotrexate, Multigated Acquisition Scan, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 145 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- 33A, placebo, azacitidine, decitabine
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 40
- States / cities
- Little Rock, Arkansas • Duarte, California • San Francisco, California + 32 more
- Conditions
- Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Interventions
- Pharmacological Treatment
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 6
- States / cities
- Louisville, Kentucky • Omaha, Nebraska • New York, New York + 3 more
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- CI 1033, PACLITAXEL, CARBOPLATIN
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Park Ridge, Illinois • Skokie, Illinois + 2 more
- Conditions
- Immune Thrombocytopenia
- Interventions
- Rilzabrutinib, Placebo
- Drug
- Lead sponsor
- Principia Biopharma, a Sanofi Company
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Francisco, California • Torrance, California + 13 more
- Conditions
- Hypertension, Pulmonary
- Interventions
- Sotatercept
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • La Jolla, California • Santa Barbara, California + 20 more
- Conditions
- Biliary Tract Cancer
- Interventions
- Zanidatamab, Cisplatin, Gemcitabine, Pembrolizumab, Durvalumab
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 21
- States / cities
- Duarte, California • Lone Tree, Colorado • Orlando, Florida + 16 more
- Conditions
- Spinal Muscular Atrophy (SMA)
- Interventions
- Prospective observational registry, Zolgensma
- Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2038
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 45 more
- Conditions
- Hypertriglyceridemia
- Interventions
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
- Drug
- Lead sponsor
- Amarin Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 702 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 80
- States / cities
- Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Interventions
- Tiespectus, Aflibercept
- Drug
- Lead sponsor
- EyeBiotech Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 52
- States / cities
- Gilbert, Arizona • Encino, California • Mountain View, California + 49 more
- Conditions
- Breast Neoplasms, Neoplasms, Hormone-Dependent
- Interventions
- Atamestane, Toremifene, Letrozole, Aromatase inhibition, Estrogen receptor blocker, Hormone therapy, Endocrine therapy, Antiestrogen therapy
- Drug · Procedure
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 842 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 49
- States / cities
- Mobile, Alabama • Tuscon, Arizona • Hot Springs, Arkansas + 46 more
- Conditions
- Breast Adenocarcinoma
- Interventions
- Bevacizumab, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,994 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2027
- U.S. locations
- 840
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 548 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Batoclimab, Placebo
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 15
- States / cities
- Pasadena, California • San Francisco, California • Torrance, California + 12 more
- Conditions
- Infection
- Interventions
- Omiganan 1% gel, Povidone-Iodine 10%
- Drug
- Lead sponsor
- Cadence Pharmaceuticals
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 1,859 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 36
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Arcadia, California + 33 more
- Conditions
- Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Refractory Pancreatic Neuroendocrine Carcinoma
- Interventions
- Sapanisertib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 405
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 260 more
- Conditions
- Herpes Simplex Infection
- Interventions
- HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine, Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 30 Years · Female only
- Enrollment
- 8,323 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2009
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
- Conditions
- Temporal Lobe Epilepsy
- Interventions
- Visualase MRI-Guided Laser Ablation
- Device
- Lead sponsor
- MedtronicNeuro
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 23
- States / cities
- Newport Beach, California • Palo Alto, California • San Francisco, California + 20 more
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- ABT-874
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 80 more